In an interview-based study in the Journal of Advanced Nursing including 15 Australian women diagnosed with postpartum psychosis over the past 10 years, women reported that they made… read more.
Americans with commercial insurance are generally told they have access to a strong network of mental health providers. But when researchers called providers listed in those networks, securing… read more.
Researchers have found that women with bipolar disorder who have regular menstrual cycles are more likely to report severe premenstrual symptoms than those with irregular cycles, according to… read more.
Various studies over the years have linked prenatal use of the pain reliever paracetamol (acetaminophen) with neurodevelopmental disorders such as autism and attention-deficit/hyperactivity disorder (ADHD) in children, but… read more.
Johnson & Johnson announced positive topline results from the pivotal Phase 3 study evaluating CAPLYTA (lumateperone) for the treatment of manic episodes with or without mixed features in… read more.
AbbVie has presented new real-world data on VRAYLAR® (cariprazine) at Psych Congress 2026 in New Orleans, including results from two prospective observational studies in major depressive disorder (MDD)… read more.
In the 1970s, psychiatric diagnoses were marked by considerable uncertainty and disagreement. Since then, organisations such as the American Psychiatric Association and the World Health Organization (WHO) have… read more.
New research led by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London, in collaboration with an international partnership of researchers, has, for the first… read more.
A study examined the brains of children at increased risk of developing schizophrenia to determine whether signs of vulnerability can be detected during childhood. The findings suggest that… read more.
Patients with inflammatory bowel disease (IBD) face a significantly higher risk of psychiatric disorders starting two to three years before diagnosis and lasting up to a decade after, according to a nationwide… read more.
Nightmares are among the most agonizing symptoms of post-traumatic stress disorder (PTSD) – a condition that can develop after exposure to severe traumatic experiences, such as disasters, serious… read more.
Otsuka announced that the FDA has granted approval of SIMTRIYO (centanafadine), a once-daily extended-release capsule for the treatment of attention-deficit hyperactivity disorder in adults and pediatric patients aged… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
